Susceptibility of penicillin-resistant and penicillin-susceptible Streptococcus pneumoniae to newer antimicrobial agents.
Agar dilution minimum inhibitory concentration (MIC) methodology, according to NCCLS guidelines, was used to test the activity of three glycopeptides (LY 333328 [LY], vancomycin [VAN], and teicoplanin [TEI]), four fluoroquinolones (trovafloxacin [TRO], BAY 12-8039 [BAY], ciprofloxacin [CIP], and ofloxacin [OFL]), five macrolide-lincosamide-streptogramin antibiotics (erythromycin [ERY], azithromycin [AZI], miocamycin [MOM], clindamycin CLN], and quinupristin-dalfopristin [SYN] against 126 Streptococcus pneumoniae strains, isolated in Lozano Blesa Hospital of Zaragoza (Spain). MIC50/MIC90 (microg/ml) values for penicillin-susceptible (PS), penicillin-intermediate (PI) and penicillin-resistant (PR) strains show an excellent antipneumococcal activity of LY 333326--a new glycopeptide, for the fluoroquinolones trovafloxacin and moxifloxacin [BAY 12-8039], and for quinupristin/dalfopristin, regardless of the resistance phenotype of the strains.
Rubio
M C
MC
Department of Microbiology, University Hospital, Zaragoza, Spain.
Goñi
P
P
Vergara
Y
Y
Seral
C
C
García
C
C
Gómez-Lus
P
P
Gómez-Lus
R
R
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D024841:Fluoroquinolones; D006020:Glycopeptides / Q000627:therapeutic use; D018942:Macrolides; D008826:Microbial Sensitivity Tests; D010403:Penicillin Resistance; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D006020:Glycopeptides; D018942:Macrolides